Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + R-CHOP + Targeted Agents in DEL DLBCL
NCT06701357Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, orelabrutinib, decitabine in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Started Dec 2024; status: recruiting.
02
Drugs
tucidinostatorelabrutinibdecitabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06701357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701357.